William-May Stubblefield

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9008495/publications.pdf

Version: 2024-02-01

		932766	887659
21	1,678	10	17
papers	citations	h-index	g-index
22	22	22	2490
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clinical Infectious Diseases, 2023, 76, e460-e468.	2.9	9
2	Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clinical Infectious Diseases, 2022, 74, 1515-1524.	2.9	144
3	Serial Thromboelastography and the Development of Venous Thromboembolism in Critically III Patients With COVID-19. , 2022, 4, e0618.		5
4	Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021. Journal of Infectious Diseases, 2022, 225, 1694-1700.	1.9	14
5	Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ, The, 2022, 376, e069761.	3.0	393
6	Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clinical Infectious Diseases, 2022, 75, S159-S166.	2.9	13
7	Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19—Nashville, Tennessee. Clinical Infectious Diseases, 2021, 72, 1645-1648.	2.9	104
8	Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. American Heart Journal, 2021, 232, 116-124.	1.2	46
9	ICU Bed Utilization During the Coronavirus Disease 2019 Pandemic in a Multistate Analysis—March to June 2020. , 2021, 3, e0361.		29
10	Thromboelastography Parameters and Platelet Count on Admission to the ICU and the Development of Venous Thromboembolism in Patients With Coronavirus Disease 2019. , 2021, 3, e0354.		4
11	Outpatient treatment of emergency department patients diagnosed with venous thromboembolism. Postgraduate Medicine, 2021, 133, 11-19.	0.9	2
12	Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021. Morbidity and Mortality Weekly Report, 2021, 70, 674-679.	9.0	245
13	Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019–2020: A Test-Negative Study. Clinical Infectious Diseases, 2021, 73, 1459-1468.	2.9	17
14	Adults Hospitalized With Coronavirus Disease 2019 (COVID-19)—United States, March–June and October–December 2020: Implications for the Potential Effects of COVID-19 Tier-1 Vaccination on Future Hospitalizations and Outcomes. Clinical Infectious Diseases, 2021, 73, S32-S37.	2.9	2
15	Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007600.	0.9	9
16	Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019–2020. Vaccine, 2021, 39, 5271-5276.	1.7	8
17	Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007956.	0.9	5
18	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA - Journal of the American Medical Association, 2021, 326, 2043.	3.8	458

#	Article	IF	CITATIONS
19	Should Cancer Patients Receive Apixaban to PreventÂVenous Thromboembolism? An Analysis of the AVERT Trial. Annals of Emergency Medicine, 2020, 75, 116-118.	0.3	1
20	Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. JAMA - Journal of the American Medical Association, 2020, 324, 1781.	3.8	133
21	Is It Time to Adjust D-dimer Thresholds to Our ClinicalÂPretest Probability? An Analysis of the PEGeDÂStudy. Annals of Emergency Medicine, 2020, 75, 778-780.	0.3	0